Which FGFR inhibitor do you prefer for patients with cholangiocarcinoma and an FGFR2 gene rearrangement?

There are 2 FGFR inhibitors which are currently FDA approved (infigratinib and pemigatinib) and multiple other FGFR inhibitors in development. Futibatinib and derazantinib may get approved soon in the future as well. Looking at data and considering clinical trial differences, I am not sure there is ...